For patients with advanced or recurrent endometrial cancer, dostarlimab plus carboplatin-paclitaxel treatment is associated with improved survival and maintenance of quality of life.

MONDAY, June 9, 2025 (HealthDay News) -- For patients with advanced or recurrent endometrial cancer, dostarlimab plus carboplatin-paclitaxel treatment is associated with improved survival and ...

A study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that combining the immunotherapy drug dostarlimab with standard chemotherapy not only provides a meaningful ...

Background: In Part 1 of the phase 3 RUBY trial (NCT03981796) in pts with pA/rEC, dostarlimab + carboplatin-paclitaxel (DOST+CP) significantly improved progression-free survival and overall survival ...

A UCLA-led study found that combining the immunotherapy drug dostarlimab with standard chemotherapy not only provides a meaningful improvement in survival for patients with advanced endometrial ...

These findings are very important for patients with early-stage dMMR tumors because it’s likely they do not need surgery or radiation if they are treated first with immunotherapy for a sufficient ...

Background: HB0025, developed by Huaota, is a novel anti-PD-L1/VEGF bispecific antibody, with VEGFR1D2 linked at the N-terminal of anti- PD-L1 antibody. Carboplatin and paclitaxel (CP) alone or in ...

Women in England with a specific type of endometrial cancer will be able to access an immunotherapy for the first time, after NICE backed use of GlaxoSmithKline's PD-1 inhibitor Jemperli via the ...

GSK’s PD-1 inhibitor Jemperli has been cleared for use by the NHS as a first-line treatment for a specific type of endometrial cancer, ... NICE recommends the use of Jemperli (dostarlimab) ...

Identifying good mid cap stocks from hundreds of options is no easy feat. Luckily, we've done the hard work for you.